The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.
A new drug doubled survival time for advanced pancreatic cancer patients, offering hope for those with limited prior treatment options.
First-in-class pan-RAS(ON) inhibitor daraxonrasib (RMC-6236) doubled median OS (13.2 vs. 6.6 months) versus chemotherapy in 2nd-line metastatic PDAC in the Phase III RASolute-302 trial, establishing a new standard of care; allele-specific combinations (G12D+ADC, G12C+farnesyl transferase inhibitor) also presented at ASCO 2026.
What the study was
- Study design
- Expert correspondence summarizing Phase III RCT (RASolute-302)
- Category
- novel_therapeutics
- Maturity
- Potentially Practice-Changing
Why it surfaced
Phase III survival benefit in mPDAC, a cancer with historically dismal 2nd-line options; first-in-class KRAS(ON) inhibitor represents a landmark in precision oncology for an unmet-need disease. High novelty, strong Phase III backing, cross-links to KRAS liquid biopsy monitoring.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.